Sinotherapeutics (SH:688247) Zhi Tong Cai Jing·2026-02-10 07:45Core Viewpoint - The company Xuantai Pharmaceutical (688247.SH) has announced its participation in the national centralized procurement for the continuation of products whose agreements have expired, with its product ursodeoxycholic acid capsules expected to be selected in this procurement process [1] Group 1: Procurement Participation - The company has submitted an application for the national centralized procurement for the first to eighth batches of products whose agreements have expired [1] - The procurement office released the proposed selection results on February 10, 2026, indicating that the company's product is likely to be selected [1] Group 2: Market Impact - The procurement process prioritizes the use of selected drugs by medical institutions, ensuring the completion of the agreed purchase volume [1] - If the company signs procurement contracts and implements them, it will help expand the sales scale of its products, increase market share, and enhance brand influence [1] - This development is expected to have a positive impact on the company's future operating performance [1]